查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1362917

癌症切片檢查市場規模、佔有率、趨勢分析報告：按類型、用途、按產品、地區和細分市場預測，2023-2030

Cancer Biopsy Market Size, Share & Trends Analysis Report By Type (Liquid Biopsy, Core Needle Biopsy), By Application (Breast Cancer, Lung Cancer), By Product (Kits & Consumables, Instruments), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 140 Pages | 商品交期: 2-10個工作天內

價格

癌症切片檢查市場的成長和趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球癌症切片檢查市場規模預計將達到516.1億美元，複合年複合成長率為8.04%。

分子醫學的進步促進了癌症分子表徵新儀器的創建。因此，液體活體組織切片的接受度和核准不斷提高預計將成為整體市場成長的主要動力。

許多新興製造商致力於開發可以改進基於內視鏡檢查的癌症切片檢查的設備。例如，2023年3月，瑞典公司BiBBInstruments AB以EndoDrill品牌在癌症切片檢查設備市場站穩了腳步。結合現有的切片檢查儀器，該公司對其切片檢查儀器進行了改進，以便能夠快速、準確地診斷癌症患者。此外，我們還提供與空心針和軟式內視鏡切片檢查相容的切片檢查儀器。開拓這些新興市場的公司預計將增加癌症切片檢查設備的可及性。

隨著液體活體組織切片的出現，基於腫瘤學的基因組資料分析和個人化醫療領域預計將顯示出良好的前景。由於液體活體組織切片提供的巨大潛力，法規機構正在積極支持這些產品的商業化並促進其在臨床實踐中的使用。液體活體組織切片有助於透過各種體液檢測癌症，並且該技術的進步使其成為獲取用於診斷目的的癌症生物材料的有吸引力的非侵入性方法。

由於生物製藥製造和基因組資料分析公司的大量投資和戰略努力，液體活體組織切片領域預計將在未來年度迅速擴張。新興企業表現出強烈的偏好與現有產業參與者建立合作關係，例如 QIAGEN Bioinformatics、Fabric Genomics、Agilent Technologies 和 SOPHiA Genetics。這種合作研究趨勢預計將進一步推動整體市場成長。

癌症切片檢查市場報告亮點

  • 到 2022 年，套件和消耗品將佔據最大的按產品市場佔有率，預計這種主導地位將在整個預測期內持續下去。從腫瘤切片檢查到液體切片檢查的重大轉變推動了試劑盒和消耗品的廣泛採用。
  • 組織切片檢查仍然是切片檢查過程的基石，並廣泛用於各種診斷用途。此外，腫瘤切片檢查主要用於個體層面的診斷和監測正在進行的腫瘤治療的有效性。
  • 從用途來看，乳癌將在 2022 年主導全球市場，並預計在預測期內保持領先地位。開放式手術切片檢查仍然是評估可疑乳房病變患者的標準，因為它在診斷此類病理具有明確的準確性。因此，該部門的收益因其在診斷乳房病變方面已被證實的有效性而得到加強。
  • 由於活躍組織和癌症基金會的集中，北美在 2022 年佔據了最大的收益佔有率。美國政府組織和私人癌症基金會的強大網路對該地區的產生收入能力做出了重大貢獻。
  • 主要市場參與企業包括 QIAGEN、ANGLE plc、Myriad Genetics、Danaher、F. Hoffmann-La Roche Ltd.、Lucence Diagnostics Pte. Ltd.、GRAIL, Inc.、Guardant Health 和 BIOCEPT, INC.。

目錄

第1章 癌症切片檢查市場：調查方法和範圍

第2章 癌症切片檢查市場：執行摘要

  • 市場預測
  • 產品和類型簡介
  • 應用程式簡介
  • 競爭形勢概覽

第3章 癌症切片檢查市場：市場變數、趨勢、範圍

  • 市場體系預測
  • 市場動態
  • 產業分析工具

第4章 癌症切片檢查市場：產品業務分析

  • 癌症切片檢查市場：產品波動分析
  • 裝置
  • 套件和消耗品
  • 服務

第5章 癌症切片檢查市場：類型業務分析

  • 癌症切片檢查市場：類型變異分析
  • 組織切片檢查
  • 液體活體組織切片
  • 其他

第6章 癌症切片檢查市場：用途業務分析

  • 癌症切片檢查市場：用途變化分析
  • 乳癌
  • 大腸直腸癌
  • 子宮頸癌
  • 肺癌
  • 攝護腺癌
  • 皮膚癌
  • 血癌
  • 腎癌
  • 肝癌
  • 胰臟癌
  • 卵巢癌
  • 其他

第7章 癌症切片檢查市場：區域業務分析

  • 區域市場簡介
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第8章 癌症切片檢查市場：競爭形勢

  • 公司分類
  • 策略規劃
  • 2022 年公司市場佔有率分析
  • 公司簡介

第9章 KOL推薦/分析師觀點

Product Code: GVR-4-68039-254-2

Cancer Biopsy Market Growth & Trends:

The global cancer biopsy market size is estimated to reach USD 51.61 billion by 2030, and is projected to expand at a CAGR of 8.04%, according to a new report by Grand View Research, Inc.. The advancement in molecular medicine has facilitated the creation of novel devices for the molecular characterization of cancers. As a result, the rising acceptance and approvals of liquid biopsies are anticipated to be significant driving forces behind the overall market growth.

Numerous emerging manufacturers are dedicated to developing instruments that can improve endoscopy-based cancer biopsies. For instance, in March 2023, BiBBInstruments AB, a Swedish company, established a strong presence in the cancer biopsy instruments market under the brand - EndoDrill. The company changed biopsy instruments that allow rapid and precise diagnosis of cancer patients related to existing biopsy instruments. Moreover, it offers biopsy instruments catering to core needles and flexible endoscopic biopsies. Such companies developing in the market are expected to upsurge the accessibility of cancer biopsy instruments.

The field of oncology-based genomic data analysis and personalized medicine is anticipated to witness lucrative prospects with the emergence of liquid biopsies. Regulatory bodies are actively backing the commercialization of these products and promoting their utilization in clinical settings due to the significant potential they offer. Liquid biopsy facilitates cancer detection through various body fluids, and the advancements in this technique have made it an appealing noninvasive approach for obtaining cancer biomaterials for diagnostic purposes.

The liquid biopsies segment is projected to experience rapid expansion in the upcoming years, driven by significant investments and strategic efforts from companies engaged in biopharmaceutical manufacturing and genomic data analysis. Emerging companies are showing a strong inclination towards forming partnerships with established industry participants like QIAGEN Bioinformatics, Fabric Genomics, Agilent Technologies, and SOPHiA Genetics. This collaborative trend is expected to further boost the overall market growth.

Cancer Biopsy Market Report Highlights:

  • In 2022, kits and consumables held the largest market share by product, and this dominance is projected to persist throughout the forecast period. The increased adoption of kits and consumables can be attributed to the notable shift from tumor biopsies to liquid biopsies
  • Tissue biopsies remain a fundamental aspect of the biopsy process and are widely utilized across various diagnostic applications. Furthermore, tumor biopsies are primarily employed for individual-level diagnosis and monitoring the efficacy of ongoing oncology treatments
  • In terms of application, breast cancer dominated the global market in 2022 and is expected to maintain its lead throughout the forecast period. Open surgical biopsy remains a reference standard for evaluating patients with suspicious breast lesions, owing to its established accuracy in diagnosing such conditions. Consequently, this segment's revenue is bolstered by its proven efficacy in breast lesion diagnosis
  • North America held the largest revenue share in 2022 owing to the concentrated pool of active organizations and cancer foundations. The strong network of government organizations and private cancer foundations in the U.S. has made significant contributions to the regional revenue generation capacity
  • Some of the key market participants are QIAGEN, ANGLE plc, Myriad Genetics, Danaher, F. Hoffmann-La Roche Ltd., Lucence Diagnostics Pte. Ltd., GRAIL, Inc., Guardant Health, and BIOCEPT, INC. among others

Table of Contents

Chapter 1 Cancer Biopsy Market: Research Methodology And Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment Definitions
      • 1.1.1.1 Product Segment
      • 1.1.1.2 Type Segment
      • 1.1.1.3 Application Segment
      • 1.1.1.4 End Use Segment
  • 1.2 Regional Scope
  • 1.3 Estimates And Forecast Timeline
  • 1.4 Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3
  • 1.5 Research Methodology
  • 1.6 Information Procurement
    • 1.6.1 Purchased Database
    • 1.6.2 Gvr's Internal Database
    • 1.6.3 Secondary Sources
    • 1.6.4 Primary Research
  • 1.7 Information Or Data Analysis
    • 1.7.1 Data Analysis Models
  • 1.8 Market Formulation & Validation
  • 1.9 Model Details
    • 1.9.1 Commodity Flow Analysis
  • 1.10 List Of Secondary Sources
  • 1.11 List Of Abbreviations

Chapter 2 Cancer Biopsy Market: Executive Summary

  • 2.1 Market Outlook
  • 2.2 Product And Type Snapshot
  • 2.3 Application Snapshot
  • 2.4 Competitive Landscape Snapshot

Chapter 3 Cancer Biopsy Market: Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Related/Ancillary Market Outlook
  • 3.2 Market Dynamics
    • 3.2.1 Market Drivers Analysis
      • 3.2.1.1 Advent Of Liquid Biopsy
      • 3.2.1.2 Transition Of Novel Oncology Diagnostics From Bench To Clinics
      • 3.2.1.3 Advancements In Quality And Payment Pertaining To Genetic Cancer Tests
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 Risks Associated With Biopsy Procedures
      • 3.2.2.2 Technical And Clinical Challenges
  • 3.3 Industry Analysis Tools
    • 3.3.1 Porter's Analysis
    • 3.3.2 Pestel Analysis

Chapter 4 Cancer Biopsy Market: Product Business Analysis

  • 4.1 Cancer Biopsy Market: Product Movement Analysis
  • 4.2 Instruments
    • 4.2.1 Instruments Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.3 Kits And Consumabkes
    • 4.3.1 Kits And Consumabels Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.4 Services
    • 4.4.1 Services Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5 Cancer Biopsy Market: Type Business Analysis

  • 5.1 Cancer Biopsy Market: Type Movement Analysis
  • 5.2 Tissue Biopsies
    • 5.2.1 Tissue Biopsies Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.2.2 Needle Biopsies
      • 5.2.2.1 Needle Biopsies Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 5.2.2.2 Fine Needle Aspiration (Fna)
      • 5.2.2.2.1 Fine Needle Aspiration (Fna) Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 5.2.2.3 Core Needle Biopsy (Cnb)
      • 5.2.2.3.1 Core Needle Biopsy (Cnb) Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.2.3 Surgical Biopsies
      • 5.2.3.1 Surgical Biopsies Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.3 Liquid Biopsies
    • 5.3.1 Liquid Biopsies Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.4 Others
    • 5.4.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6 Cancer Biopsy Market: Application Business Analysis

  • 6.1 Cancer Biopsy Market: Application Movement Analysis
  • 6.2 Breast Cancer
    • 6.2.1 Breast Cancer Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.3 Colorectal Cancer
    • 6.3.1 Colorectal Cancer Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.4 Cervical Cancers
    • 6.4.1 Cervical Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.5 Lung Cancers
    • 6.5.1 Lung Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.6 Prostate Cancers
    • 6.6.1 Prostate Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.7 Skin Cancers
    • 6.7.1 Skin Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.8 Blood Cancers
    • 6.8.1 Blood Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.9 Kidney Cancers
    • 6.9.1 Kidney Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.10 Liver Cancers
    • 6.10.1 Liver Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.11 Pancreatic Cancers
    • 6.11.1 Pancreatic Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.12 Ovarian Cancers
    • 6.12.1 Ovarian Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.13 Others
    • 6.13.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7 Cancer Biopsy Market: Regional Business Analysis

  • 7.1 Regional Market Snapshot
  • 7.2 North America
    • 7.2.1 North America Cancer Biopsy Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.2.2 U.S.
      • 7.2.2.1 U.S. Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.2.2.2 Key Country Dynamics
      • 7.2.2.3 Regulatory Framework
      • 7.2.2.4 Reimbursement Scenario
    • 7.2.3 Canada
      • 7.2.3.1 Canada Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.2.3.2 Key Country Dynamics
      • 7.2.3.3 Regulatory Framework
      • 7.2.3.4 Reimbursement Scenario
  • 7.3 Europe
    • 7.3.1 Europe Cancer Biopsy Market, 2018 - 2030 (USD Million)
    • 7.3.2 Uk
      • 7.3.2.1 Uk Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.3.2.2 Key Country Dynamics
      • 7.3.2.3 Regulatory Framework
      • 7.3.2.4 Reimbursement Scenario
    • 7.3.3 Germany
      • 7.3.3.1 Germany Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.3.3.2 Key Country Dynamics
      • 7.3.3.3 Regulatory Framework
      • 7.3.3.4 Reimbursement Scenario
    • 7.3.4 Spain
      • 7.3.4.1 Spain Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.3.4.2 Key Country Dynamics
      • 7.3.4.3 Regulatory Framework
      • 7.3.4.4 Reimbursement Scenario
    • 7.3.5 France
      • 7.3.5.1 France Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.3.5.2 Key Country Dynamics
      • 7.3.5.3 Regulatory Framework
      • 7.3.5.4 Reimbursement Scenario
    • 7.3.6 Italy
      • 7.3.6.1 Italy Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.3.6.2 Key Country Dynamics
      • 7.3.6.3 Regulatory Framework
      • 7.3.6.4 Reimbursement Scenario
    • 7.3.7 Denmark
      • 7.3.7.1 Denmark Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.3.7.2 Key Country Dynamics
      • 7.3.7.3 Regulatory Framework
      • 7.3.7.4 Reimbursement Scenario
    • 7.3.8 Sweden
      • 7.3.8.1 Sweden Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.3.8.2 Key Country Dynamics
      • 7.3.8.3 Regulatory Framework
      • 7.3.8.4 Reimbursement Scenario
    • 7.3.9 Norway
      • 7.3.9.1 Norway Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.3.9.2 Key Country Dynamics
      • 7.3.9.3 Regulatory Framework
      • 7.3.9.4 Reimbursement Scenario
  • 7.4 Asia Pacific
    • 7.4.1 Asia-Pacific Cancer Biopsy Market, 2018 - 2030 (USD Million)
    • 7.4.2 Japan
      • 7.4.2.1 Japan Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.4.2.2 Key Country Dynamics
      • 7.4.2.3 Regulatory Framework
      • 7.4.2.4 Reimbursement Scenario
    • 7.4.3 China
      • 7.4.3.1 China Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.4.3.2 Key Country Dynamics
      • 7.4.3.3 Regulatory Framework
      • 7.4.3.4 Reimbursement Scenario
    • 7.4.4 India
      • 7.4.4.1 India Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.4.4.2 Key Country Dynamics
      • 7.4.4.3 Regulatory Framework
      • 7.4.4.4 Reimbursement Scenario
    • 7.4.5 South Korea
      • 7.4.5.1 South Korea Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.4.5.2 Key Country Dynamics
      • 7.4.5.3 Regulatory Framework
      • 7.4.5.4 Reimbursement Scenario
    • 7.4.6 Thailand
      • 7.4.6.1 Thailand Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.4.6.2 Key Country Dynamics
      • 7.4.6.3 Regulatory Framework
      • 7.4.6.4 Reimbursement Scenario
    • 7.4.7 Australia
      • 7.4.7.1 Australia Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.4.7.2 Key Country Dynamics
      • 7.4.7.3 Regulatory Framework
      • 7.4.7.4 Reimbursement Scenario
  • 7.5 Latin America
    • 7.5.1 Latin America Cancer Biopsy Market, 2018 - 2030 (USD Million)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.5.2.2 Key Country Dynamics
      • 7.5.2.3 Regulatory Framework
      • 7.5.2.4 Reimbursement Scenario
    • 7.5.3 Mexico
      • 7.5.3.1 Mexico Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.5.3.2 Key Country Dynamics
      • 7.5.3.3 Regulatory Framework
      • 7.5.2.4 Reimbursement Scenario
    • 7.5.4 Argentina
      • 7.5.4.1 Argentina Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.5.4.2 Key Country Dynamics
      • 7.5.4.3 Regulatory Framework
      • 7.5.4.4 Reimbursement Scenario
  • 7.6 MEA
    • 7.6.1 MEA Cancer Biopsy Market, 2018 - 2030 (USD Million)
    • 7.6.2 South Africa
      • 7.6.2.1 South Africa Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.6.2.2 Key Country Dynamics
      • 7.6.2.3 Regulatory Framework
      • 7.6.2.4 Reimbursement Scenario
    • 7.6.3 Saudi Arabia
      • 7.6.3.1 Saudi Arabia Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.6.3.2 Key Country Dynamics
      • 7.6.3.3 Regulatory Framework
      • 7.6.3.4 Reimbursement Scenario
    • 7.6.4 Uae
      • 7.6.4.1 Uae Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.6.4.2 Key Country Dynamics
      • 7.6.4.3 Regulatory Framework
      • 7.6.2.4 Reimbursement Scenario
    • 7.6.5 Kuwait
      • 7.6.5.1 Kuwait Cancer Biopsy Market, 2018 - 2030 (USD MILLION)
      • 7.6.5.2 Key Country Dynamics
      • 7.6.5.3 Regulatory Framework
      • 7.6.5.4 Reimbursement Scenario

Chapter 8 Cancer Biopsy Market: Competitive Landscape

  • 8.1 Company Categorization
  • 8.2 Strategy Mapping
    • 8.2.1 New product launch
    • 8.2.2 Partnerships
    • 8.2.3 Acquisition
    • 8.2.4 Collaboration
    • 8.2.5 Funding
  • 8.3 Company Market Share Analysis, 2022
  • 8.4 Company Profiles
    • 8.4.1 QIAGEN
      • 8.4.1.1 Company overview
      • 8.4.1.2 Financial performance
      • 8.4.1.3 Product benchmarking
      • 8.4.1.4 Strategic initiatives
    • 8.4.2 ILLUMINA, INC.
      • 8.4.2.1 Company overview
      • 8.4.2.2 Financial performance
      • 8.4.2.3 Product benchmarking
      • 8.4.2.4 Strategic initiatives
    • 8.4.3 ANGLE PLC
      • 8.4.3.1 Company overview
      • 8.4.3.2 Financial performance
      • 8.4.3.3 Product benchmarking
      • 8.4.3.4 Strategic initiatives
    • 8.4.4 BD (BECTON, DICKINSON AND COMPANY)
      • 8.4.4.1 Company overview
      • 8.4.4.2 Financial performance
      • 8.4.4.3 Product benchmarking
      • 8.4.4.4 Strategic initiatives
    • 8.4.5 MYRIAD GENETICS
      • 8.4.5.1 Company overview
      • 8.4.5.1.1 Counsyl, Inc.
      • 8.4.5.2 Financial performance
      • 8.4.5.3 Product benchmarking
      • 8.4.5.4 Strategic initiatives
    • 8.4.6 HOLOGIC, INC.
      • 8.4.6.1 Company overview
      • 8.4.6.2 Financial performance
      • 8.4.6.3 Product benchmarking
    • 8.4.7 BIOCEPT, INC.
      • 8.4.7.1 Company overview
      • 8.4.7.2 Financial performance
      • 8.4.7.3 Product benchmarking
      • 8.4.7.4 Strategic initiatives
    • 8.4.8 THERMO FISHER SCIENTIFIC, INC.
      • 8.4.8.1 Company overview
      • 8.4.8.2 Financial performance
      • 8.4.8.3 Product benchmarking
      • 8.4.8.4 Strategic initiatives
    • 9.4.9 DANAHER
      • 8.4.9.1 Company overview
      • 8.4.9.2 Beckman Coulter, Inc
      • 8.4.9.3 Radiometer Medical ApS
      • 8.4.9.4 HemoCue AB
      • 8.4.9.5 Financial performance
      • 8.4.9.6 Product benchmarking
    • 8.4.10 F. HOFFMANN-LA ROCHE LTD.
      • 8.4.10.1 Company overview
      • 8.4.10.2 FOUNDATION MEDICINE, INC.
      • 8.4.10.3 Financial performance
      • 8.4.10.4 Product benchmarking
    • 8.4.11 LUCENCE DIAGNOSTICS PTE. LTD.
      • 8.4.11.1 Company overview
      • 8.4.11.2 Financial performance
      • 8.4.11.3 Product benchmarking
      • 8.4.11.4 Strategic initiatives
    • 8.4.12 GRAIL, INC.
      • 8.4.12.1 Company overview
      • 8.4.12.2 Financial performance
      • 8.4.12.3 Product benchmarking
      • 8.4.12.4 Strategic initiatives
    • 8.4.13 GUARDANT HEALTH
      • 8.4.13.1 Company overview
      • 8.4.13.2 Financial performance
      • 8.4.13.3 Product benchmarking
      • 8.4.13.4 Strategic initiatives
    • 8.4.14 EXACT SCIENCES CORPORATION
      • 8.4.14.1 Company overview
      • 8.4.14.2 Financial performance
      • 8.4.14.3 Product benchmarking
      • 8.4.14.4 Strategic initiatives
    • 8.4.15 FREENOME HOLDINGS, INC.
      • 8.4.15.1 Company overview
      • 8.4.15.2 Financial performance
      • 8.4.15.3 Product benchmarking
      • 8.4.15.4 Strategic initiatives
    • 8.4.16 BIODESIX (INTEGRATED DIAGNOSTICS)
      • 8.4.16.1 Company overview
      • 8.4.16.2 Financial performance
      • 8.4.16.3 Product benchmarking
      • 8.4.16.4 Strategic initiatives
    • 8.4.17 ONCIMMUNE
      • 8.4.17.1 Company overview
      • 8.4.17.2 Financial performance
      • 8.4.17.3 Product benchmarking
      • 8.4.17.4 Strategic initiatives
    • 8.4.18 EPIGENOMICS AG.
      • 8.4.18.1 Company overview
      • 8.4.18.2 Financial performance
      • 8.4.18.3 Product benchmarking
      • 8.4.18.4 Strategic initiatives
    • 8.4.19 HELIOHEALTH (LABORATORY FOR ADVANCED MEDICINE)
      • 8.4.19.1 Company overview
      • 8.4.19.2 Financial performance
      • 8.4.19.3 Product benchmarking
      • 8.4.19.4 Strategic initiatives
    • 8.4.20 GENESYSTEMS, INC. (GENESYS BIOLABS)
      • 8.4.20.1 Company overview
      • 8.4.20.2 Financial performance
      • 8.4.20.3 Product benchmarking
      • 8.4.20.4 Strategic initiatives
    • 8.4.21 CHRONIX BIOMEDICAL, INC.
      • 8.4.21.1 Company overview
      • 8.4.21.2 Financial performance
      • 8.4.21.3 Product benchmarking
      • 8.4.21.4 Strategic initiatives
    • 8.4.22 PERSONAL GENOME DIAGNOSTICS INC.
      • 8.4.22.1 Company overview
      • 8.4.22.2 Financial performance
      • 8.4.22.3 Product benchmarking
      • 8.4.22.4 Strategic initiatives
    • 8.4.23 NATERA, INC.
      • 8.4.23.1 Company overview
      • 8.4.23.2 Financial performance
      • 8.4.23.3 Product benchmarking
      • 8.4.23.4 Strategic initiatives
    • 8.4.24 PERSONALIS INC.
      • 8.4.16.1 Company overview
      • 8.4.24.2 Financial performance
      • 8.4.24.3 Product benchmarking
      • 8.4.24.4 Strategic initiatives

Chapter 9 KOL Recommendations/Analyst Perspective

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 North America cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 5 North America cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 7 U.S. cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 8 U.S. cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 9 Canada cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 10 Canada cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 11 Canada cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 12 Europe cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 13 Europe cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 14 Europe cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 15 Germany cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 16 Germany cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 17 Germany cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 18 UK cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 19 UK cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 20 UK cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 21 France cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 22 France cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 23 France cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 24 Spain cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 25 Spain cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 26 Spain cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 27 Italy cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 28 Italy cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 29 Italy cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 30 Denmark cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 31 Denmark cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 32 Denmark cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 33 Sweden cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 34 Sweden cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 35 Sweden cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 36 Norway cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 37 Norway cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 38 Norway cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 39 Asia Pacific cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 42 Japan cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 43 Japan cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 44 Japan cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 45 China cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 46 China cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 47 China cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 48 India cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 49 India cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 50 India cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 51 South Korea cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 52 South Korea cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 53 South Korea cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 54 Thailand cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 55 Thailand cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 56 Thailand cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 57 Australia cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 58 Australia cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 59 Australia cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 60 Latin America cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 61 Latin America cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 62 Latin America cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 63 Brazil cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 64 Brazil cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 65 Brazil cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 66 Mexico cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 67 Mexico cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 68 Mexico cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 69 Argentina cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 70 Argentina cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 71 Argentina cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 72 MEA cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 73 MEA cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 74 MEA cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 75 South Africa cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 76 South Africa cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 77 South Africa cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 78 Saudi Arabia cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 79 Saudi Arabia cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 80 Saudi Arabia cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 81 UAE cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 82 UAE cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 83 UAE cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 84 Kuwait cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 85 Kuwait cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 86 Kuwait cancer biopsy market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Cancer biopsy market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Segment snapshot
  • Fig. 12 Competitive landscape
  • Fig. 13 Cancer Biopsy Market Value, 2022 (USD Billion)
  • Fig. 14 Cancer Biopsy - Industry value chain analysis
  • Fig. 15 Cancer biopsy market dynamics
  • Fig. 16 Cancer biopsy market: PORTER's analysis
  • Fig. 17 Cancer biopsy market: PESTEL analysis
  • Fig. 18 Cancer biopsy market: By application: Key takeaways
  • Fig. 19 Cancer biopsy market, by application: Market share, 2022 & 2030
  • Fig. 20 Genetic disorders market, 2018 - 2030 (USD Million)
  • Fig. 21 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 22 Personalized medicine market, 2018 - 2030 (USD Million)
  • Fig. 23 Other application market, 2018 - 2030 (USD Million)
  • Fig. 24 Cancer biopsy market: By product: Key takeaways
  • Fig. 25 Cancer biopsy market, by product: Market share, 2022 & 2030
  • Fig. 26 Instruments market, 2018 - 2030 (USD Million)
  • Fig. 27 Kits and consumables market, 2018 - 2030 (USD Million)
  • Fig. 28 Services market, 2018 - 2030 (USD Million)
  • Fig. 29 Cancer biopsy market: By type: Key takeaways
  • Fig. 30 Cancer biopsy market, by type: Market share, 2022 & 2030
  • Fig. 31 Tissue biopsies market, 2018 - 2030 (USD Million)
  • Fig. 32 Needle biopsies market, 2018 - 2030 (USD Million)
  • Fig. 33 Fine needle aspiration (FNA) market, 2018 - 2030 (USD Million)
  • Fig. 34 Core needle biopsy (CNB) market, 2018 - 2030 (USD Million)
  • Fig. 35 Surgical biopsies market, 2018 - 2030 (USD Million)
  • Fig. 36 Liquid biopsies market, 2018 - 2030 (USD Million)
  • Fig. 37 Others market, 2018 - 2030 (USD Million)
  • Fig. 38 Cancer biopsy market: By application: Key takeaways
  • Fig. 39 Cancer biopsy market, by application: Market share, 2022 & 2030
  • Fig. 40 Breast cancer market, 2018 - 2030 (USD Million)
  • Fig. 41 Colorectal cancer market, 2018 - 2030 (USD Million)
  • Fig. 42 Cervical cancers market, 2018 - 2030 (USD Million)
  • Fig. 43 Lung cancers market, 2018 - 2030 (USD Million)
  • Fig. 44 Prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 45 Skin cancer market, 2018 - 2030 (USD Million)
  • Fig. 46 Blood cancers market, 2018 - 2030 (USD Million)
  • Fig. 47 Kidney cancers market, 2018 - 2030 (USD Million)
  • Fig. 48 Liver cancer market, 2018 - 2030 (USD Million)
  • Fig. 49 Pancreatic cancers market, 2018 - 2030 (USD Million)
  • Fig. 50 Ovarian cancers market, 2018 - 2030 (USD Million)
  • Fig. 51 Others market, 2018 - 2030 (USD Million)
  • Fig. 52 Cancer biopsy market revenue, by region, 2022 & 2030, (USD Million)
  • Fig. 53 Regional marketplace: Key takeaways
  • Fig. 54 Regional marketplace: Key takeaways
  • Fig. 55 North America: SWOT analysis
  • Fig. 56 North America cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Reimbursement procurement process
  • Fig. 59 U.S. cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Canada cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Europe: SWOT analysis
  • Fig. 63 Europe cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Germany cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 UK cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 France color-correcting classes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Italy cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Spain cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Denmark cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Sweden cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Norway cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Asia Pacific: SWOT analysis
  • Fig. 81 Asia Pacific cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Reimbursement procurement process
  • Fig. 84 Japan cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Key country dynamics
  • Fig. 86 China cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 India cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 Australia cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 South Korea cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Key country dynamics
  • Fig. 94 Thailand cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Latin America: SWOT analysis
  • Fig. 96 Latin America cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Key country dynamics
  • Fig. 98 Brazil cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Key country dynamics
  • Fig. 100 Mexico cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Key country dynamics
  • Fig. 102 Argentina cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 MEA: SWOT analysis
  • Fig. 104 Middle East & Africa cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 Key country dynamics
  • Fig. 106 South Africa cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 107 Key country dynamics
  • Fig. 108 Saudi Arabia cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 Key country dynamics
  • Fig. 110 UAE cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 111 Key country dynamics
  • Fig. 112 Kuwait cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 113 Key company categorization
  • Fig. 114 Company market position analysis
  • Fig. 115 Strategic framework